Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$41.14

0.26 (0.64%)

, ALKS

Alkermes

$42.37

0.07 (0.17%)

10:25
10/18/16
10/18
10:25
10/18/16
10:25

Leerink biotech analysts hold an analyst/industry conference call

Analysts discuss the recent data, controversies and catalysts for treating postpartum depression on an Analyst/Industry conference call to be held on October 18 at 11 am.

SAGE

Sage Therapeutics

$41.14

0.26 (0.64%)

ALKS

Alkermes

$42.37

0.07 (0.17%)

  • 18

    Oct

  • 06

    Nov

  • 14

    Dec

SAGE Sage Therapeutics
$41.14

0.26 (0.64%)

10/07/16
GSCO
10/07/16
NO CHANGE
GSCO
Smid-cap Biotech sector upgraded to Attractive from Neutral at Goldman
Goldman analyst Salveen Richter upgraded the Smid-cap biotechnology to Attractive and said he favors and companies with near-term pipeline data or regulatory events where he has conviction.Names he recommends are Buy rated BioMarin (BMRN), bluebird bio (BLUE), GW Pharma (GWPH), Incyte (INCY), Kite (KITE), and Sage (SAGE).
10/04/16
LEER
10/04/16
INITIATION
Target $68
LEER
Outperform
SAGE Therapeutics reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of SAGE Therapeutics with an Outperform rating and $68 price target.
09/13/16
RAJA
09/13/16
INITIATION
Target $75
RAJA
Outperform
SAGE Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Christopher Raymond initiated SAGE Therapeutics with an Outperform and a $75 price target. Raymond likes the setup on SAGE shares as key validation of its unique central nervous system drug development approach nears through pivotal SAGE-547 data, expected 1H 2017. Combining this with a pipeline holding numerous unmodeled call options and a platform capable of generating novel agents in a space lacking innovation, he believes shares will move higher.
09/07/16
ROTH
09/07/16
NO CHANGE
Target $149
ROTH
Buy
Ligand has 'major catalyst' ahead, says Roth Capital
Roth Capital analyst Joseph Pantginis says Ligand (LGND) is expecting a "major catalyst" this month namely the Phase IIb sparsentan data in focal segmental glomerulosclerosis patients being developed by partner Retrophin (RTRX). In a separate note to investors, Pantginis also said that the Breakthrough Therapy Designation of SAGE Therapeutics' (SAGE) '547 for postpartum depression may expedite its development and approval for use in the clinic, noting that the company has an agreement of 3% royalty payment to Ligand for potential sales of the drug. The analyst recommends steady accumulation of Ligand's stock as he anticipates that current revenue streams from partnered products and the broad "in development" portfolio are poised to drive significant growth in the near and longer term. He reiterates a Buy rating and $149 price target on Ligand's shares.
ALKS Alkermes
$42.37

0.07 (0.17%)

10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.
10/04/16
LEER
10/04/16
INITIATION
Target $57
LEER
Outperform
Alkermes reinstated with an Outperform at Leerink
Leerink analyst Paul Matteis resumed coverage of Alkermes with an Outperform rating and $57 price target.
09/27/16
JEFF
09/27/16
NO CHANGE
Target $62
JEFF
Buy
Alkermes sees significant room for Vivitrol upside, says Jefferies
Alkermes yesterday at its Vivitrol-focused event highlighted that the opioid treatment is still in the early stages of growth, Jefferies analyst Biren Amin tells investors in a research note. The company estimates that Vivitrol is currently capturing only 2% average market share and believes room for upside is significant, the analyst writes. He keeps a Buy rating on Alkermes with a $62 price target.
09/27/16
SBSH
09/27/16
NO CHANGE
Target $53
SBSH
Neutral
Alkermes price target raised to $53 from $44 at Citi
Citi analyst Liav Abraham raised her price target for Alkermes to $53 after the company hosted an investor event to overview the various aspects of Vivitrol. Alkermes' execution on a "unique commercial model," which targets the differing opioid addiction population needs on a state-by-state basis, is likely to drive robust volume growth going forward, particularly in the Medicaid patient population, Abraham tells investors in a research note. The analyst raised her estimates for Vivitrol but remains cautious on the FORWARD-5 data for ALKS 5461 due out in Q4. As such, Abraham keeps a Neutral rating on Alkermes.

TODAY'S FREE FLY STORIES

ELS

Equity Lifestyle

$87.87

-0.23 (-0.26%)

16:35
09/19/17
09/19
16:35
09/19/17
16:35
Hot Stocks
Equity Lifestyle provides update on Hurricane Irma impact, reaffirms guidance »

Equity LifeStyle…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Oct

  • 30

    Jan

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:35
09/19/17
09/19
16:35
09/19/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

MXWL

Maxwell

$6.29

-0.24 (-3.68%)

16:34
09/19/17
09/19
16:34
09/19/17
16:34
Hot Stocks
Maxwell enters into Amended and Restated Agreement with Viex »

Maxwell Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRCY

Mercury Systems

$48.29

0.84 (1.77%)

16:33
09/19/17
09/19
16:33
09/19/17
16:33
Hot Stocks
Mercury Systems receives $3.8M order for advanced electronic warfare application »

Mercury Systems announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HF

HFF Inc.

$37.12

0.12 (0.32%)

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
HFF Inc. announces sale of office in Raleigh-Durham, NC for $105.5M »

Holliday Fenoglio Fowler…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Options
Preliminary option volume of 13.8M today »

Preliminary option volume…

RYAM

Rayonier Advanced Materials

16:30
09/19/17
09/19
16:30
09/19/17
16:30
Hot Stocks
Rayonier Advanced Materials estimates impact from Hurricane Irma »

Rayonier Advanced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALOG

Analogic

$75.95

-1.35 (-1.75%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
Earnings
Analogic sees FY18 EPS $2.70 to $2.90, two estimates consensus $2.80 »

Sees FY18 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

, TMUS

T-Mobile

$65.42

3.62 (5.86%)

16:28
09/19/17
09/19
16:28
09/19/17
16:28
General news
On The Fly: Top stock stories for Tuesday »

Stocks searched for a…

AMZN

Amazon.com

$969.86

-4.33 (-0.44%)

TMUS

T-Mobile

$65.42

3.62 (5.86%)

S

Sprint

$8.20

0.52 (6.77%)

VZ

Verizon

$49.34

1.25 (2.60%)

SFTBF

SoftBank

$82.75

4.45 (5.68%)

DTEGY

Deutsche Telekom

$18.75

0.68 (3.76%)

BOBE

Bob Evans

$77.41

4.48 (6.14%)

POST

Post Holdings

$86.36

0.52 (0.61%)

RAD

Rite Aid

$2.40

-0.33 (-12.09%)

WBA

Walgreens Boots Alliance

$81.21

-1.39 (-1.68%)

KSS

Kohl's

$45.38

0.49 (1.09%)

AZO

AutoZone

$535.19

-28.21 (-5.01%)

SNCR

Synchronoss

$9.82

-6.93 (-41.37%)

REV

Revlon

$17.05

1.05 (6.56%)

BBY

Best Buy

$52.76

-4.59 (-8.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 19

    Sep

  • 19

    Sep

  • 21

    Sep

  • 22

    Sep

  • 27

    Sep

  • 28

    Sep

  • 02

    Oct

  • 19

    Oct

  • 22

    Oct

  • 30

    Oct

  • 09

    Nov

  • 16

    May

FDX

FedEx

$216.00

0.92 (0.43%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Earnings
FedEx sees FY18 ex-items EPS $12.00-$12.80, consensus $13.38 »

The company is lowering…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

CSTM

Constellium

$10.00

0.4 (4.17%)

16:26
09/19/17
09/19
16:26
09/19/17
16:26
Hot Stocks
Constellium signs contract with Pilatus to support jet aircraft program »

Constellium announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 02

    Oct

GEMP

Gemphire Therapeutics

$9.65

0.54 (5.93%)

16:25
09/19/17
09/19
16:25
09/19/17
16:25
Conference/Events
Gemphire Therapeutics to hold a conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

SERV

ServiceMaster

$47.06

0.1 (0.21%)

16:23
09/19/17
09/19
16:23
09/19/17
16:23
Initiation
ServiceMaster initiated  »

ServiceMaster initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSC

Harsco

$19.90

0.4 (2.05%)

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Harsco gets orders from D.C and Sacramento, CA for safety systems »

Harsco Corporation's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

, TPGI

Now owned by PKY

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Sabra to acquire 49% equity interest in senior housing managed by Enlivant »

Sabra Health Care,…

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

TPGI

Now owned by PKY

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

, TPGI

Now owned by PKY

16:22
09/19/17
09/19
16:22
09/19/17
16:22
Hot Stocks
Sabra to acquire 49% equity interest in senior housing managed by Enlivant »

Sabra Health Care,…

SBRA

Sabra Health Care

$22.97

-0.47 (-2.01%)

TPGI

Now owned by PKY

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

BBBY

Bed Bath & Beyond

16:21
09/19/17
09/19
16:21
09/19/17
16:21
Hot Stocks
Bed Bath & Beyond reports Q2 SSS from customer-facing digital channels up 20%+ »

Comparable sales from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:20
09/19/17
09/19
16:20
09/19/17
16:20
Hot Stocks
Bed Bath & Beyond sees over $150M in savings from transformational initiatives »

The company believes the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:20
09/19/17
09/19
16:20
09/19/17
16:20
Hot Stocks
Bed Bath & Beyond repurchased about $56M of common stock in Q2 »

During the fiscal 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

FDX

FedEx

$216.00

0.92 (0.43%)

16:19
09/19/17
09/19
16:19
09/19/17
16:19
Earnings
FedEx reports Q1 adjusted EPS $2.51, consensus $3.09 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 21

    Sep

  • 25

    Sep

ALOG

Analogic

$75.95

-1.35 (-1.75%)

16:18
09/19/17
09/19
16:18
09/19/17
16:18
Earnings
Analogic reports Q4 EPS 0c, two estimate consensus 50c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:18
09/19/17
09/19
16:18
09/19/17
16:18
Earnings
Bed Bath & Beyond sees FY17 EPS about $3.00, consensus $4.01 »

The Company's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

$NSD

NASDAQ Market Internals

16:17
09/19/17
09/19
16:17
09/19/17
16:17
Technical Analysis
NASDAQ market internals summary »

Volume was average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBBY

Bed Bath & Beyond

$27.03

-0.27 (-0.99%)

16:16
09/19/17
09/19
16:16
09/19/17
16:16
Hot Stocks
Breaking Hot Stocks news story on Bed Bath & Beyond »

Bed Bath & Beyond…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

BBBY

Bed Bath & Beyond

16:16
09/19/17
09/19
16:16
09/19/17
16:16
Earnings
Bed Bath & Beyond reports Q2 EPS 67c including charges, consensus 95c »

Reports Q2 revenue $2.9B,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.